Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer

Key Points Question In women with locally advanced carcinoma of the cervix who are candidates for chemotherapy and radiotherapy, does adding fludeoxyglucose F 18 positron emission tomography–computed tomography (PET-CT) to staging with CT of the abdomen and pelvis detect more extensive disease and influence therapy? Findings In a randomized clinical trial, 44 of 112 patients receiving PET-CT compared with 14 of 56 patients receiving CT alone received more extensive chemotherapy and radiotherapy or palliative treatment, a nonsignificant difference. Five percent of patients in each group were treated with palliative intent. Meaning In this trial among women with locally advanced carcinoma of the cervix, there was no significant difference between PET-CT plus CT vs CT alone, possibly because the trial was underpowered.

[1]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[2]  W. Ju,et al.  Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: Meta‐analysis , 2010, Cancer science.

[3]  Gautam G. Rao,et al.  ACR Appropriateness Criteria® Definitive Therapy for Early-Stage Cervical Cancer , 2012, American journal of clinical oncology.

[4]  J. Shirlaw.  THE METABOLISM OF TUMOURS , 1931 .

[5]  A. Fyles,et al.  The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  Y. Brandberg,et al.  Health-related Quality of Life Measured by the EORTC QLQ-C30: Reference Values From a Large Sample of the Swedish Population , 2000 .

[7]  M. Stockler,et al.  A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174). , 2014 .

[8]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[9]  H. Lynch,et al.  Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .

[10]  G. Guyatt,et al.  Users' Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. , 2000, JAMA.

[11]  Gautam G. Rao,et al.  ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer. , 2012, Gynecologic oncology.

[12]  J. Iglehart,et al.  Prioritizing comparative-effectiveness research--IOM recommendations. , 2009, The New England journal of medicine.

[13]  E. McGlynn,et al.  The quality of health care delivered to adults in the United States. , 2003, The New England journal of medicine.

[14]  A. Laupacis,et al.  Evidence-based approach to the introduction of positron emission tomography in ontario, Canada. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M Hatanaka,et al.  Transport of sugars in tumor cell membranes. , 1974, Biochimica et biophysica acta.

[17]  F. Fazio,et al.  Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. , 2006, Radiology.

[18]  S. Pecorelli,et al.  Revised FIGO staging for carcinoma of the cervix , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Yen,et al.  A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy. , 2010, International journal of radiation oncology, biology, physics.

[21]  R. Hustinx,et al.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.

[22]  G. Lyman,et al.  Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology , 2015, Genetics in Medicine.

[23]  Y. Brandberg,et al.  Health-related Quality of Life Measured by the EORTC QLQ-C30: Reference Values From a Large Sample of the Swedish Population , 2000 .

[24]  M. Haider,et al.  Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. , 2014, JAMA.